Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06012734
Title LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients (CoLBAt)
Acronym CoLBAt
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors The Netherlands Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD


No variant requirements are available.